# A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy

> **NCT03764072** · PHASE2 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 250 (actual)

## Conditions studied

- Acute Pain

## Interventions

- **DRUG:** VX-150
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03764072
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-12
- **Primary completion:** 2019-01-17
- **Final completion:** 2019-01-25
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2022-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03764072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03764072, "A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03764072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*